Kazia Therapeutics Limited (KZIA)
| Market Cap | 168.69M +1,779.3% |
| Revenue (ttm) | 1.27M -24.2% |
| Net Income | -15.21M |
| EPS | -6.82 |
| Shares Out | 13.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 414,432 |
| Open | 12.00 |
| Previous Close | 12.16 |
| Day's Range | 11.77 - 12.62 |
| 52-Week Range | 4.86 - 17.40 |
| Beta | 2.15 |
| Analysts | Strong Buy |
| Price Target | 29.17 (+136.96%) |
| Earnings Date | Mar 30, 2026 |
About KZIA
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain met... [Read more]
Financial Performance
In fiscal year 2025, Kazia Therapeutics's revenue was 1.83 million, a decrease of -26.28% compared to the previous year's 2.48 million. Losses were -20.70 million, -22.69% less than in 2024.
Financial numbers in AUD Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for KZIA stock is "Strong Buy." The 12-month stock price target is $29.17, which is an increase of 136.96% from the latest price.
News
Kazia Therapeutics price target raised to $40 from $34 at BTIG
BTIG raised the firm’s price target on Kazia Therapeutics (KZIA) to $40 from $34 and keeps a Buy rating on the shares after the company announced new preclinical and translational…
Kazia Therapeutics announces new preclinical, translational data on paxalisib
Kazia Therapeutics (KZIA) announced new preclinical and translational data showing that its lead asset, paxalisib, reduced tumor burden, the total amount of cancer in the body, by 52% in microsatellit...
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerate...
Kazia Therapeutics expands paxalisib trial into HR+/HER2- breast cancer
Kazia Therapeutics (KZIA) announced new preclinical data demonstrating the safety and anti-tumor activity of paxalisib in HR+/HER2- breast cancer, including evidence that paxalisib resensitized CDK4/6...
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
Preclinical Data Show Paxalisib Combined With Standard-of-Care Therapy Is Well Tolerated and Produces Statistically Significant Antitumor Activity Three-Arm Expansion of the Ongoing TNBC Trial Will Ev...
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
Company to host a corporate update call Tuesday, September 1st at 8:00am ET SYDNEY, Aug. 31, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focu...
Kazia Therapeutics 2.58M share Spot Secondary priced at $15.50
Leerink and Guggenheim acted as joint book running managers for the offering.
Kazia Therapeutics announces pricing of $120M public offering
Kazia Therapeutics (KZIA) announced the pricing of its previously announced tranched registered public offering of (i) 2,580,000 American Depositary Shares, each representing five hundred ordinary sha...
Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram ca...
Kazia Therapeutics reports 100% clinical benefit rate in breast cancer treatment
Kazia Therapeutics (KZIA) announced new data showing its lead asset, paxalisib, achieved a 100% clinical benefit rate in six evaluable patients with Stage IV triple-negative breast cancer, or TNBC. Fi...
Kazia Therapeutics announces offering of ADS, warrants
Kazia Therapeutics (KZIA) announced that it has commenced a tranched registered public offering of (i) American Depositary Shares, each representing five hundred ordinary shares of the company, no par...
Kazia Therapeutics Limited Announces Proposed Public Offering
SYDNEY, Aug. 27, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram ca...
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Durable Complete Metabolic Response Ongoing Since November 2025 All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reduc...
Kazia Therapeutics initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $29 price target
Kazia Therapeutics initiated with a Buy at Canaccord on paxalisib potential
As previously reported, Canaccord initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $29 price target The firm sees lead asset paxalisib in triple negative breast cancer as…
Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
Clinically relevant perioperative studies demonstrate elimination of residual disease and prevention of metastatic spread, supported by complementary translational patient data Clinically relevant per...
Kazia Therapeutics initiated with a Buy at BTIG
BTIG analyst Kambiz Yazdi initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $34 price target Kazia is advancing paxalisib, which the firm calls “not simply a broader…
Kazia Therapeutics initiated with a Buy at Lake Street
Lake Street initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $32 price target The ongoing Phase 1b ABC-Pax study and its associated expanded access program have together…
Kazia Therapeutics appoints James Levine as CFO
Kazia Therapeutics (KZIA) appointed James Levine as CFO, effective June 1. Most recently, Levine served as CFO of Cardiff Oncology, a clinical-stage oncology company developing a PLK1 inhibitor therap...
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed to repro...
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazi...
Kazia Therapeutics appoints Sudha Rao as Chief Scientific Officer
Kazia Therapeutics (KZIA) appointed Sudha Rao as Chief Scientific Officer, or CSO. Dr. Rao has more than 20 years of experience spanning pharmaceutical R&D, biotechnology, and early clinical developme...
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the ap...
Kazia Therapeutics initiated with a Buy at Laidlaw
Laidlaw initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $25 price target Kazia is developing paxalisib, a novel dual PI3K/mTOR inhibitor, as a potential triple negative breast…
Kazia Therapeutics in-licenses drug development platform from QIMR Berghofer
Kazia Therapeutics (KZIA) announced the in-licensing of a SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The platform includes use of an AI-integrated epigenetic drug discov...